Hanking-KY Plans to List on Innovation Board by End of May, Initiates Global Licensing Negotiations for New Anti-Cancer Drug
Hanking-KY, a company specializing in immuno-oncology drug development, plans to list on the Innovation Board by the end of May. Its new anti-cancer drug, HCB101, secured an early licensing deal worth US02 million last year and is now in global licensing negotiations.
📋 Article Processing Timeline
- 📰 Published: May 8, 2026 at 19:16
- 🔍 Collected: May 8, 2026 at 19:32 (15 min after Published)
- 🤖 AI Analyzed: May 8, 2026 at 21:23 (1h 51m after Collected)
Central News Agency (CNA reporter Ho Hsiu-ling, Taipei, 8th) - Hanking-KY, a company specializing in the research and development of new immuno-oncology drugs, is expected to be listed on the Innovation Board by the end of May. Chairman Liu Shih-kao stated that the company''s core technology platform has advanced the development of eight innovative protein biologic drugs. Among them, the new anti-cancer drug HCB101 completed an early-stage licensing deal worth US02 million last year and is currently in global licensing negotiations with international pharmaceutical companies, targeting opportunities in the global immuno-oncology market.
Hanking held a media briefing today. Hanking is a next-generation immunotherapy company with trifunctional fusion protein biologic technology. Founder and Chairman Liu Shih-kao previously worked at multinational pharmaceutical companies such as BMS (Bristol-Myers Squibb) and Amgen. He returned to Taiwan in 2020 to found Hanking, focusing on R&D in the two major fields of cancer and autoimmune diseases. Liu personally holds a 40% stake in the company.
He said that Hanking''s core ''FBDB multi-functional fusion protein technology platform'' has eight innovative protein biologic drugs under R&D and process development, showing anti-cancer potential and continuously obtaining multiple patents. Two leading drug candidates, HCB101 and HCB301, have entered the clinical trial stage. HCB101 is currently undergoing clinical trials and has shown outstanding performance in indications such as head and neck cancer, gastric cancer, triple-negative breast cancer, and colorectal cancer.
Liu Shih-kao mentioned that HCB101 completed an early-stage licensing deal for US02 million last year, exclusively granting the market development and sales rights for mainland China and other specific regions to the biopharmaceutical company Fosun Henlius. Currently, global licensing negotiations are ongoing with more than 10 world-leading international pharmaceutical companies, with potential partners entering the due diligence stage.
Furthermore, HCB301, mainly used for treating various solid tumors or hematological malignancies, is gradually releasing Phase I clinical data and has begun exploratory partnership discussions. He said the company will accelerate the commercialization of its new drugs through various profit models such as licensing, co-development, or mergers and acquisitions to create revenue opportunities.
Looking ahead, he stated that Hanking will continue to deepen its focus on immuno-oncology therapy, integrating clinical resources and R&D capabilities from the U.S., China, and Taiwan to accelerate the clinical progress and global licensing of HCB101 and HCB301. The company also plans to submit an IND (Investigational New Drug) application for its innovative drugs targeting autoimmune diseases, such as HCB206. (Editor: Huang Kuo-lun) 1150508
Hanking held a media briefing today. Hanking is a next-generation immunotherapy company with trifunctional fusion protein biologic technology. Founder and Chairman Liu Shih-kao previously worked at multinational pharmaceutical companies such as BMS (Bristol-Myers Squibb) and Amgen. He returned to Taiwan in 2020 to found Hanking, focusing on R&D in the two major fields of cancer and autoimmune diseases. Liu personally holds a 40% stake in the company.
He said that Hanking''s core ''FBDB multi-functional fusion protein technology platform'' has eight innovative protein biologic drugs under R&D and process development, showing anti-cancer potential and continuously obtaining multiple patents. Two leading drug candidates, HCB101 and HCB301, have entered the clinical trial stage. HCB101 is currently undergoing clinical trials and has shown outstanding performance in indications such as head and neck cancer, gastric cancer, triple-negative breast cancer, and colorectal cancer.
Liu Shih-kao mentioned that HCB101 completed an early-stage licensing deal for US02 million last year, exclusively granting the market development and sales rights for mainland China and other specific regions to the biopharmaceutical company Fosun Henlius. Currently, global licensing negotiations are ongoing with more than 10 world-leading international pharmaceutical companies, with potential partners entering the due diligence stage.
Furthermore, HCB301, mainly used for treating various solid tumors or hematological malignancies, is gradually releasing Phase I clinical data and has begun exploratory partnership discussions. He said the company will accelerate the commercialization of its new drugs through various profit models such as licensing, co-development, or mergers and acquisitions to create revenue opportunities.
Looking ahead, he stated that Hanking will continue to deepen its focus on immuno-oncology therapy, integrating clinical resources and R&D capabilities from the U.S., China, and Taiwan to accelerate the clinical progress and global licensing of HCB101 and HCB301. The company also plans to submit an IND (Investigational New Drug) application for its innovative drugs targeting autoimmune diseases, such as HCB206. (Editor: Huang Kuo-lun) 1150508